硼替佐米巩固或维持治疗在套细胞淋巴瘤免疫化疗及自体干细胞移植后的随机II期研究
CALGB/Alliance 50403是一项随机II期试验,评估在增强剂量R-CHOP/甲氨蝶呤、以大剂量阿糖胞苷为基础的干细胞动员、CBV自体移植及利妥昔单抗后,加用硼替佐米巩固或维持治疗套细胞淋巴瘤的耐受性与疗效。共入组151例,118例(80%)接受ASCT,102例(68%)随机分组。两臂均达到主要终点,中位PFS显著大于4年(P < .001);8年PFS在巩固臂为54.1%(95%CI 40.9%-71.5%),维持臂为64.4%(95%CI 51.8%-79.0%)。与59909研究相比,50403移植患者的PFS显著更长;诱导后MRD阴性者PFS和OS均显著更好;高增殖特征与不良结局相关。
要点
- 移植后硼替佐米巩固或维持均可行且有效,但毒性显著。
- 两臂中位PFS均显著超过4年(P < .001),8年PFS巩固臂54.1%、维持臂64.4%。
- 诱导后骨髓MRD阴性者PFS和OS显著更好,高增殖特征提示不良结局。
核心结论
- 移植后加用硼替佐米巩固或维持治疗在套细胞淋巴瘤中有效且可耐受,但毒性显著。
- 长期随访比较提示,在移植后加用硼替佐米巩固或维持可带来PFS获益。
研究设计与样本
- CALGB/Alliance 50403为随机II期试验,入组151例套细胞淋巴瘤患者。
- 118例(80%)接受自体干细胞移植,102例(68%)随机分组至硼替佐米巩固或维持。
- 主要终点为从随机化开始计算的PFS,并评估增殖特征、Ki67及诱导后骨髓MRD。
主要发现
- 两臂均达到主要终点,中位PFS显著大于4年(P < .001)。
- 巩固臂8年PFS为54.1%(95%CI 40.9%-71.5%),维持臂为64.4%(95%CI 51.8%-79.0%)。
- 50403移植患者的PFS显著长于59909研究中的移植患者。
- 诱导后MRD阴性者PFS和OS均显著更好,高增殖特征与不良结局相关。
关键数值与推荐
- 巩固方案:硼替佐米1.3 mg/m2 IV,3周周期第1、4、8、11天,共4周期,第90天开始。
- 维持方案:硼替佐米1.6 mg/m2 IV,每周一次×4,每8周重复,持续18个月,第90天开始。
临床怎么用
- 套细胞淋巴瘤自体移植后可考虑硼替佐米巩固或维持,但需密切监测毒性。
- 诱导后骨髓MRD阴性提示PFS和OS更优,可用于风险分层。
局限性
- 原文未报告两组间PFS或OS的直接统计学比较结果。
- 毒性显著,可能影响临床耐受性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Immunochemotherapy followed by autologous transplant (ASCT) in CALGB/Alliance 59909 achieved a median progression-free survival (PFS) in mantle cell lymphoma (MCL) of 5 years, but late recurrences occurred. We evaluated tolerability and efficacy of adding post-transplant bortezomib consolidation (BC) or maintenance (BM) to this regimen in CALGB/Alliance 50403, a randomized phase II trial. Following augmented-dose R-CHOP/ methotrexate, high-dose cytarabine-based stem cell mobilization, cyclophosphamide/carmustine/etoposide (CBV) autotransplant, and rituximab, patients were randomized to BC (1.3 mg/m2 IV days 1, 4, 8, 11 of a 3-week cycle for four cycles) or BM (1.6 mg/m2 IV once weekly × 4 every 8 weeks for 18 months) beginning day 90. The primary endpoint was PFS, measured from randomization for each arm. Proliferation signature, Ki67, and postinduction minimal residual disease (MRD) in bone marrow were assessed. Of 151 patients enrolled; 118 (80%) underwent ASCT, and 102 (68%) were randomized. Both arms met the primary endpoint, with median PFS significantly greater than 4 years (P < .001). The 8-year PFS estimates in the BC and BM arms were 54.1% (95% CI 40.9%-71.5%) and 64.4% (95% 51.8%-79.0%), respectively. Progression-free survival was significantly longer for transplanted patients on 50403 compared with those on 59909. Both the PFS and OS were significantly better for those who were MRD-negative post-induction. The high risk proliferation signature was associated with adverse outcome. Both BM and BC were efficacious and tolerable, although toxicity was significant. The comparison between studies 50403 and 59909 with long-term follow up suggests a PFS benefit from the addition of BC or BM post- transplant.
引用
- Kaplan LD, Maurer MJ, Stock W, et al. Bortezomib consolidation or maintenance following immunochemotherapy and autologous stem cell transplantation for mantle cell lymphoma: CALGB/Alliance 50403. Am J Hematol. 2020. PMID: 32170769. doi:10.1002/ajh.25783
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。